Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Cash from Financing Activities (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Cash from Financing Activities for 17 consecutive years, with $21000.0 as the latest value for Q1 2026.

  • Quarterly Cash from Financing Activities changed N/A to $21000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.0 million through Mar 2026, changed N/A year-over-year, with the annual reading at $51.5 million for FY2025, 6.18% up from the prior year.
  • Cash from Financing Activities for Q1 2026 was $21000.0 at Achieve Life Sciences, down from $6.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $56.1 million in Q1 2024, with the low at -$8.1 million in Q3 2024.
  • Average Cash from Financing Activities over 5 years is $7.2 million, with a median of $682000.0 recorded in 2024.
  • The widest YoY moves for Cash from Financing Activities: up 119282.98% in 2024, down 101.0% in 2024.
  • Achieve Life Sciences' Cash from Financing Activities stood at $17.7 million in 2022, then decreased by 14.01% to $15.2 million in 2023, then crashed by 95.52% to $682000.0 in 2024, then surged by 818.33% to $6.3 million in 2025, then crashed by 99.66% to $21000.0 in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Cash from Financing Activities are $21000.0 (Q1 2026), $6.3 million (Q4 2025), and $4.0 million (Q3 2025).